GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES

GlaxoSmithKline Plc has signed a deal to licence in a substantial portfolio of tumour-specific antigens from the international Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.
The Scotsman